<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567656</url>
  </required_header>
  <id_info>
    <org_study_id>RP6530-1401</org_study_id>
    <secondary_id>124584</secondary_id>
    <nct_id>NCT02567656</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma</brief_title>
  <official_title>A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K
      delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety: Treatment-Emergent AE; Treatment-Related AE, SAE and Clinical significant AE; Dose
      Limiting Toxicities (DLT). PK: Peak Plasma Concentration (Cmax), Area under the plasma
      concentration versus time curve (AUC), Time of Maximum concentration observed (Tmax).
      Efficacy: Overall Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS)
      and Duration of Response.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of RP6530</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants with Treatment-Related Adverse Events as Assessed by CTACE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) with RP6530</measure>
    <time_frame>8 months</time_frame>
    <description>No of patients with partial and complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) with RP6530</measure>
    <time_frame>24 months</time_frame>
    <description>The time period from the response achieved in patient until the disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>28 days</time_frame>
    <description>Peak Plasma Concentration (Cmax) of RP6530</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Lymphoma, T-Cell, Peripheral</condition>
  <condition>Lymphoma, T-Cell, Cutaneous</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP6530 administered orally twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RP6530</intervention_name>
    <description>Tablet starting at 200 mg</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>PI3k inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory to or relapsed after at least 1 prior treatment line.

          -  ECOG performance status ≤2

          -  Patients must be ≥18 years of age

          -  Able to give a written informed consent.

        Exclusion Criteria:

          -  Any cancer therapy in the last 3 weeks or limited palliative radiation &lt;2 weeks

          -  Patients with HBV, HCV or HIV infection

          -  Previous therapy with GS-1101 (CAL-101, Idelalisib), IPI-145 (Duvelisib), TGR-1202 or
             any drug that specifically inhibits PI3K/ mTOR (including temsirolimus, everolimus),
             AKT or BTK Inhibitor (including Ibrutinib) in last 6 months

          -  Patients on immunosuppressive therapy including systemic corticosteroids.

          -  Patients with known history of liver disorders.

          -  Patients with uncontrolled Diabetes Type I or Type II

          -  Any severe and/or uncontrolled medical conditions or other conditions that could
             affect their participation in the study.

          -  Women who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Auris Huen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Center, Houston, Tx.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0944</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CTCL</keyword>
  <keyword>PTCL</keyword>
  <keyword>RP6530</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

